Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news